Regeneron Expands Precision Medicine Pipeline With $2.3B Parabilis Collaboration
TARRYTOWN, N.Y., May 18, 2026 Regeneron Pharmaceuticals has announced a major strategic collaboration with Parabilis Medicines valued at up...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
TARRYTOWN, N.Y., May 18, 2026 Regeneron Pharmaceuticals has announced a major strategic collaboration with Parabilis Medicines valued at up...
PARIS, France, May 18, 2026 Sanofi has announced positive Phase 2 ElevAATe trial results demonstrating that investigational therapy efdoralprin...
CAMBRIDGE, Mass., May 12, 2026 AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell...
Basel, Switzerland, December 2, 2025 —Roche has announced the launch of a rapid 15-minute point-of-care PCR test capable of...
Tarrytown, New York & Somerville, Massachusetts, December 1, 2025 — Regeneron and Tessera Therapeutics have announced a global collaboration...
